FDA and Regulation

FDA Says More Than 1,600 AI-Enabled Medical Devices Are Authorized

5 min read By AI Medicine Now Editorial

The FDA now reports that more than 1,600 AI-enabled medical devices have been authorized for marketing in the United States. The count shows how quickly AI has entered regulated medical products. It does not mean 1,600 general-purpose clinical AI systems have been approved, that every listed device improves outcomes, or that a listed product will work in a particular hospital.

What the FDA AI Device Count Includes

The FDA regulates medical devices based on intended use and risk. An AI-enabled function may reach the market through 510(k) clearance, De Novo classification, or premarket approval. One submission can include one or more AI-enabled functions, while one company may hold multiple authorizations for different products or indications.

The public list covers:

The listed decision date, submission number, product, company, and medical panel help a buyer identify the regulatory record that belongs to a specific product.

What FDA AI Authorization Does Not Prove

  • It does not authorize use outside the stated indication.
  • It does not establish that the product fits local workflow.
  • It does not replace review of study design and patient population.
  • It does not guarantee equal performance across equipment, sites, or patient groups.
  • It does not show whether the product reduces burden or improves outcomes after deployment.
  • It does not remove the need for monitoring after software updates.

How Hospitals Can Use the FDA AI Device List

Start with the exact product name and submission number. Read the intended use, user, patient population, input data, output, contraindications, and performance summary. Then compare that regulatory record with the vendor's current product description. If the marketing claim is broader than the cleared use, ask the vendor to explain the difference.

Next, connect the regulatory record to the local decision. A radiology triage tool needs workflow, alert-burden, and turnaround-time review. A detection tool needs threshold and false-positive analysis. A predictive monitor needs calibration, action rules, and a plan for changing prevalence.

Why AI Device Lifecycle Oversight Is Growing

AI-enabled devices can change through software updates, new data, and revised functions.

FDA guidance on predetermined change control plans and lifecycle management is meant to make anticipated modifications and validation expectations clearer.

Buyers still need:

  • contract terms that identify version changes
  • notice requirements
  • local retesting
  • rollback
  • monitoring responsibility

What to Watch in FDA AI Regulation

The useful story is no longer only how many devices appear on the list. It is whether the public data make intended use, evidence, modifications, and real-world performance easier to evaluate. AIMedicineNow will track count changes alongside the clinical questions the count cannot answer.

Related FDA and Medical AI Coverage

Reviewed: September 28, 2026. Next review: October 28, 2026.

Frequently Asked Questions

How many AI-enabled medical devices has the FDA authorized?

The FDA reports more than 1,600 AI-enabled medical devices authorized for marketing in the United States as of September 2026.

Does an FDA listing prove a device improves patient outcomes?

No. Authorization is tied to a regulatory submission and intended use. Buyers still need evidence, workflow review, local validation, and monitoring.

How should a hospital use the FDA AI device list?

Use the product name and submission number to find the intended use, evidence, patient population, output, limitations, and regulatory history for the exact product being evaluated.

Related Reading

Sources